Short Term
Mean Reversion
Very Strong
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Weak
Earnings
Strong
Growth
Earnings
Neutral
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.2.9454.7200
Address
Frenchs Forest 20 Rodborough Road Sydney, New South Wales (NSW) 2086
Description
Syntara Ltd. is a pharmaceutical research company, which engages in the development and commercialization of healthcare products for fibrotic and inflammatory diseases. Its respiratory products include bronchitol and aridol. The company was founded by Brett Charlton and William B. Cowden on May 29, 1998 and is headquartered in Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.01 - 0.06
Trade Value (12mth)
AU$8,602.00
1 week
7.89%
1 month
78.26%
YTD
115.79%
1 year
-25.45%
All time high
4.31
EPS 3 yr Growth
N/A
EBITDA Margin
-121.40%
Operating Cashflow
-$7m
Free Cash Flow Return
-64.30%
ROIC
-100.40%
Interest Coverage
-70.50
Quick Ratio
2.10
Shares on Issue (Fully Dilluted)
727m
HALO Sector
Healthcare
Next Company Report Date
14-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
01 July 24 |
Investor presentation
×
Investor presentation |
24 June 24 |
Change of Share Registry Management Services
×
Change of Share Registry Management Services |
12 June 24 |
SNT to present in MST Access Hidden Gems Webinar
×
SNT to present in MST Access Hidden Gems Webinar |
24 May 24 |
Change of registry address notification
×
Change of registry address notification |
17 May 24 |
Investor Webinar Presentation
×
Investor Webinar Presentation |
30 April 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
30 April 24 |
Quarterly Activities Report
×
Quarterly Activities Report |
30 April 24 |
Presentation for quarterly shareholder briefing
×
Presentation for quarterly shareholder briefing |
30 April 24 |
Updated company investor presentation
×
Updated company investor presentation |
30 April 24 |
Application for quotation of securities - SNT
×
Application for quotation of securities - SNT |
29 April 24 |
Notification of cessation of securities - SNT
×
Notification of cessation of securities - SNT |
24 April 24 |
SNT Quarterly Report and Investor Briefing
×
SNT Quarterly Report and Investor Briefing |
15 April 24 |
Change in substantial holding
×
Change in substantial holding |
10 April 24 |
Phase 2 Trial Reaches 50% Recruitment
×
Phase 2 Trial Reaches 50% Recruitment |
19 March 24 |
Investor presentation - NWR Virtual Healthcare Conference
×
Investor presentation - NWR Virtual Healthcare Conference |
14 March 24 |
SNT to present at NWR Virtual Healthcare Conference
×
SNT to present at NWR Virtual Healthcare Conference |
06 March 24 |
Investor Presentation
×
Investor Presentation |
04 March 24 |
Change in substantial holding
×
Change in substantial holding |
29 February 24 |
Application for quotation of securities - SNT
×
Application for quotation of securities - SNT |
29 February 24 |
Half Yearly Report and Accounts
×
Half Yearly Report and Accounts |
14 February 24 |
SNT to Trial New Cancer Indication Following MRFF Grant
×
SNT to Trial New Cancer Indication Following MRFF Grant |
14 February 24 |
Notification regarding unquoted securities - SNT
×
Notification regarding unquoted securities - SNT |
14 February 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
14 February 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
09 February 24 |
Change in substantial holding
×
Change in substantial holding |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.